Frequencies of the Defective CYP2C19 Alleles Responsible for the Mephenytoin Poor Metabolizer Phenotype in Various Oriental, Caucasian, Saudi Arabian and American Black Populations
Overview
Pharmacology
Affiliations
The 4'-hydroxylation of S-mephenytoin is polymorphic in man. The poor metabolizer (PM) phenotype exhibits a lower frequency in Caucasians (2-5%) compared to Oriental populations (13-23%). Previous studies from our laboratory have described two mutations (CYP2C19m1 and CYP2C19m2) which account for approximately 100% of Oriental and approximately 85% of Caucasian PM alleles. The present study examined whether the genotype predicted the phenotype in Japanese, Filipino and Saudi Arabian populations, and compared the frequencies of the defective CYP2C19 alleles in these populations with those found in European-Americans, Chinese-Taiwanese, and African-Americans from North Carolina. Among 53 Japanese, 15% were PMs and among 52 Filipinos 23% were PMs. Among 97 Saudi Arabians, only two were PMs. There was a complete concordance between genotype and phenotype in all three populations. The incidence of CYP2C19m1 was 0.23 (95% confidence limits 0.15-0.31) in Japanese, 0.39 (95% confidence limits 0.29-0.48) in Filipinos, 0.32 (95% confidence limits 0.26-0.38) in Chinese-Taiwanese, 0.15 (95% confidence limits 0.10-0.20) in Saudi Arabians, 0.13 (95% confidence limits 0.08-0.17) in European-Americans, and 0.25 in African-Americans from North Carolina (95% confidence limits (0.14-0.31). The incidence of CYP2C19m1 in Saudi Arabians was similar to that found in European-Americans, and significantly lower than that found in Oriental populations or African-Americans (p < 0.05). CYP2C19m2 was not found in European-Americans, Saudi Arabians or African-Americans (95% confidence limits 0-0.014). The incidence of CYP2C19m2 in the three Oriental populations ranged from 0.10 (95% confidence limits 0.05-0.17) in Japanese and 0.08 (95% confidence limits 0.03-0.13) in Filipinos to 0.06 (95% confidence limits 0.03-0.08) in Chinese-Taiwanese.
Van Nguyen K, Vu Q, Tran M, Nguyen H, Le C, Dang B Glob Pediatr Health. 2023; 10:2333794X231216556.
PMID: 38073663 PMC: 10699157. DOI: 10.1177/2333794X231216556.
Achieving Equity in Asian American Healthcare: Critical Issues and Solutions.
Obra J, Lin B, doan L, Palaniappan L, Srinivasan M J Asian Health. 2023; 1(1).
PMID: 37872960 PMC: 10593109. DOI: 10.59448/jah.v1i1.3.
Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.
Hsu A, Tamma P, Fisher B Antimicrob Agents Chemother. 2022; 66(7):e0215621.
PMID: 35766509 PMC: 9295552. DOI: 10.1128/aac.02156-21.
Alrajeh K, Roman Y Per Med. 2022; 19(4):327-339.
PMID: 35748236 PMC: 9318053. DOI: 10.2217/pme-2021-0175.
Pharmacogenetics in Primary Headache Disorders.
Belyaeva I, Subbotina A, Eremenko I, Tarasov V, Chubarev V, Schioth H Front Pharmacol. 2022; 12:820214.
PMID: 35222013 PMC: 8866828. DOI: 10.3389/fphar.2021.820214.